{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"3.6","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, as determined by ICR, or death due to any cause, if occurring sooner than progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).","id":"OG000","title":"Retifanlimab 500 mg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. Median PFS time was estimated using the Kaplan-Meier method. The confidence interval for median PFS time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to 16.8 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}